Deferiprone (L1)

DRUG3 trials

Sponsors

Carelon Research, Lipomed

Conditions

Beta-ThalassemiaCardiovascular DiseasesHeart DiseasesHemochromatosis

Phase 2

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

TerminatedNCT00115349

Carelon ResearchBeta-Thalassemia, Cardiovascular Diseases, Heart Diseases

Start: 2005-06-30End: 2009-04-30Updated: 2018-03-01

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

CompletedNCT00349453

LipomedHemochromatosis

Start: 2005-03-31End: 2011-05-31Updated: 2011-12-12

Phase 3

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

CompletedNCT00350662

LipomedHemochromatosis

Start: 2002-01-31Updated: 2012-11-19

Related Papers

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

2011-12-1614 citations